EPL and Aclairo Combine Preclinical Services Expertise
EPL is pleased to announce that it has acquired Aclairo Pharmaceutical Development Group, Inc. (Aclairo) which provides independent and objective nonclinical, regulatory, and clinical ADME/DMPK expert strategy and implementation to the pharmaceutical and drug device industries.
“Aclairo’s team of industry and ex-FDA experts have developed a specialized consultancy in drug and device development strategy with breadth and depth in the biologic, pharmaceutical and device arenas. Their expertise includes regulatory strategy and oversight, pharmacology, toxicology, DMPK, and overall program design, placement, management and interpretation.” said Dr. Jerry Hardisty, EPL’s President and CEO.
Jerry F. Hardisty, DVM, Diplomate ACVP, Fellow IATP
CEO / President / Senior Pathologist
Dr. Hardisty joined EPL as a staff pathologist in 1976 where he gained extensive expertise in nonclinical safety assessment through direct microscopic evaluation of tissues and contribution to resolution of toxicologic pathology issues related to chemical and drug development. Dr. Hardisty has worked with the NCI/NTP Carcinogenesis Testing Program for over 30 years and has participated in the publication and presentation of significant results of the NCI/NTP Pathology Quality Assessment Programs. More